Talacotuzumab

• CAT Number: I042201
• CAS Number: 1826831-79-1
• Purity: ≥95%

Talacotuzumab (JNJ 56022473; CSL 362) is an IgG1-type fully humanized, CD123-neutralizing monoclonal antibody containing a modified Fc structure. Talacotuzumab has KDs of 0.43 nM, 188 nM, 46 nM, 16.8 nM for CD123, CD32b/c, CD16-158F, CD16-158V, respectively. Talacotuzumab inhibits IL-3 binding to CD123, antagonizing IL-3 signaling in target cells. Talacotuzumab has mutated the Fc region to increase affinity for CD16 (FcγRIIIa), thereby enhancing antibody-dependent cell-mediated cytotoxicity (ADCC). Talacotuzumab is highly effective in vivo reducing leukemic cell growth in acute myeloid leukemia (AML) xenograft mouse models[1][2][3][4].
Talacotuzumab (JNJ 56022473; CSL 362) strongly mediates ADCC of TF-1 cells with an ic50 of 5 ng/ml (33 pM)[1].
Talacotuzumab (1 μg/ml; pretreatment for 24 hours) inhibits TLR7-stimulated (Imiquimod; HY-B0180; 0.5 μM; for 6 days) and TLR9-stimulated (CpG C; 0.5 μM; for 6 days) IFN-α production in both SLE donors and healthy donors plasmacytoid dendritic cells (pDCs) and basophils, whereas TLR4-stimulated (LPS; HY-D1056; 10 μg/ml) production is not significantly reduced. Talacotuzumab inhibits TLR7- and TLR9-induced plasmablast expansion and proliferation by depletion of plasmacytoid dendritic cells (pDCs)[2].
Talacotuzumab (JNJ 56022473; CSL 362; 300 μg; ip; thrice weekly for 5 weeks) results in a significant delay in tumor growth compared with an isotype control in acute myeloid leukaemia mice xenografts[1].
Talacotuzumab (1, 10, 30 mg/kg; s.c.; single injection) has maximal serum concentrations at 48 hours of ~12, 190, and 380 μg/ml at doses of 1, 10, and 30 mg/kg in naive cynomolgus monkeys, respectively[2].

Reference

[1]. S J Busfield, et al. Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC. Leukemia. 2014 Nov;28(11):2213-21.
 [Content Brief]

[2]. Shereen Oon, et al. A cytotoxic anti-IL-3Rα antibody targets key cells and cytokines implicated in systemic lupus erythematosus. JCI Insight. 2016 May 5;1(6):e86131.
 [Content Brief]

[3]. Erwin M Lee, et al. Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient mice. Haematologica. 2015 Jul;100(7):914-26.
 [Content Brief]

[4]. L H Xie, et al. CD123 target validation and preclinical evaluation of ADCC activity of anti-CD123 antibody CSL362 in combination with NKs from AML patients in remission. Blood Cancer J. 2017 Jun 2;7(6):e567.
 [Content Brief]